AMGN Stock Analysis: Amgen | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 201.932m USD | 12M Return: 29.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.08B
EPS Trend: 31.8%
Qual. Beats: 3
Rev. Trend: 98.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amgen is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics across a broad range of disease areas, including autoimmune disorders, oncology, cardiovascular disease, osteoporosis, and rare conditions. Its marketed portfolio spans well-established franchises such as Enbrel (rheumatoid arthritis and psoriasis), Prolia/XGEVA (osteoporosis and bone-related events), Repatha (cholesterol-related cardiovascular risk), KYPROLIS (multiple myeloma), and TEPEZZA (thyroid eye disease), alongside newer offerings like IMDELLTRA and TAVNEOS. As one of the worlds largest independent biotechnology companies, the business model depends on heavy research and development investment, long product lifecycles under patent protection, and recurring revenue from biologics administered in clinical settings.
The company sells primarily to healthcare providers, including physicians, dialysis centers, hospitals, and pharmacies, channeling distribution through pharmaceutical wholesale distributors. Amgen has also built a network of collaboration and co-development agreements with partners such as AstraZeneca (TEZSPIRE), BeiGene (oncology), UCB (EVENITY), Kyowa Kirin (rocatinlimab), and BeOne Medicines (Aimovig), which extend its reach into geographies and indications it does not fully cover on its own.
The company was incorporated in 1980 and has been publicly traded since its 1983 IPO on NASDAQ under the ticker AMGN.
- MariTide obesity drug pivotal trial results drive valuation
- Prolia and Enbrel biosimilars pressure legacy franchise sales
- IRA Medicare price negotiations impact Part D revenue
| Net Income: 7.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.92 > 1.0 |
| NWC/Revenue: 17.51% < 20% (prev 11.49%; Δ 6.02% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.8b > Net Income 7.80b |
| Net Debt (45.3b) to EBITDA (16.7b): 2.71 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (544.0m) vs 12m ago 0.55% < -2% |
| Gross Margin: 71.46% > 18% (prev 63.00%; Δ 8.46% > 0.5%) |
| Asset Turnover: 40.95% > 50% (prev 38.19%; Δ 2.76% > 0%) |
| Interest Coverage Ratio: 4.36 > 6 (EBIT TTM 11.8b / Interest Expense TTM 2.70b) |
| A: 0.07 (Total Current Assets 31.5b - Total Current Liabilities 25.0b) / Total Assets 92.5b |
| B: -0.27 (Retained Earnings -24.6b / Total Assets 92.5b) |
| C: 0.13 (EBIT TTM 11.8b / Avg Total Assets 90.9b) |
| D: 0.11 (Book Value of Equity 9.19b / Total Liabilities 83.3b) |
| Altman-Z'' = 0.58 = B |
| DSRI: 1.03 (Receivables 9.14b/8.13b, Revenue 37.2b/34.1b) |
| GMI: 0.88 (GM 63.00% / 71.46%) |
| AQI: 0.92 (AQ_t 0.57 / AQ_t-1 0.62) |
| SGI: 1.09 (Revenue 37.2b / 34.1b) |
| TATA: -0.03 (NI 7.80b - CFO 10.8b) / TA 92.5b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 368.10 with a total of 1,940,816 shares traded. Over the past week, the price has changed by +2.09%, over one month by +6.47%, over three months by +9.08% and over the past year by +29.43%.
Current recommended Stop Loss: 350.50 (which is 4.8% or 2 ATR below the current price).
Amgen has received a consensus analysts rating of 3.63. Therefore, it is recommended to hold AMGN.
- StrongBuy: 10
- Buy: 5
- Hold: 14
- Sell: 1
- StrongSell: 2
| Analysts Target Price | 354.8 | -3.6% |
P/E Trailing = 26.0369
P/E Forward = 16.2338
P/S = 5.4254
P/B = 21.2201
P/EG = 1.9804
Revenue TTM = 37.2b USD
EBIT TTM = 11.8b USD
EBITDA TTM = 16.7b USD
Long Term Debt = 51.9b USD (from longTermDebt, last quarter)
Short Term Debt = 5.44b USD (from shortTermDebt, last quarter)
Debt = 57.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.3b USD (calculated: Debt 57.3b - CCE 12.0b)
Enterprise Value = 247b USD (202b + Debt 57.3b - CCE 12.0b)
Interest Coverage Ratio = 4.36 (Ebit TTM 11.8b / Interest Expense TTM 2.70b)
EV/FCF = 28.76x (Enterprise Value 247b / FCF TTM 8.60b)
FCF Yield = 3.48% (FCF TTM 8.60b / Enterprise Value 247b)
FCF Margin = 23.09% (FCF TTM 8.60b / Revenue TTM 37.2b)
Net Margin = 20.95% (Net Income TTM 7.80b / Revenue TTM 37.2b)
Gross Margin = 71.46% ((Revenue TTM 37.2b - Cost of Revenue TTM 10.6b) / Revenue TTM)
Gross Margin QoQ = 68.16% (prev 81.91%)
Tobins Q-Ratio = 2.67 (Enterprise Value 247b / Total Assets 92.5b)
Interest Expense / Debt = 4.72% (Interest Expense 2.70b / Debt 57.3b)
Taxrate = 14.16% (1.29b / 9.09b)
NOPAT = 10.1b (EBIT 11.8b * (1 - 14.16%))
Current Ratio = 1.26 (Total Current Assets 31.5b / Total Current Liabilities 25.0b)
Debt / Equity = 6.24 (Debt 57.3b / totalStockholderEquity, last quarter 9.19b)
Debt / EBITDA = 2.71 (Net Debt 45.3b / EBITDA 16.7b)
Debt / FCF = 5.27 (Net Debt 45.3b / FCF TTM 8.60b)
Total Stockholder Equity = 8.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.58% (Net Income 7.80b / Total Assets 92.5b)
RoE = 89.41% (Net Income TTM 7.80b / Total Stockholder Equity 8.72b)
RoCE = 19.45% (EBIT 11.8b / Capital Employed (Equity 8.72b + L.T.Debt 51.9b))
RoIC = 14.23% (NOPAT 10.1b / Invested Capital 71.1b)
WACC = 6.09% (E(202b)/V(259b) * Re(6.67%) + D(57.3b)/V(259b) * Rd(4.72%) * (1-Tc(0.14)))
Discount Rate = 6.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.22 | Cagr: 0.33%
[DCF] Terminal Value 73.10% ; FCFF base≈9.52b ; Y1≈8.35b ; Y5≈6.75b
[DCF] Fair Price = 116.8 (EV 108b - Net Debt 45.3b = Equity 63.0b / Shares 539.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 31.75 | EPS CAGR: 1.48% | SUE: 0.97 | # QB: 3
Revenue Correlation: 98.67 | Revenue CAGR: 14.06% | SUE: 0.23 | # QB: 0
EPS current Quarter (2026-06-30): EPS=5.60 | Chg30d=+0.24% | Revisions=-62% | Analysts=26
EPS next Quarter (2026-09-30): EPS=5.76 | Chg30d=-0.06% | Revisions=-38% | Analysts=26
EPS current Year (2026-12-31): EPS=22.39 | Chg30d=-0.08% | Revisions=+21% | GrowthEPS=+2.5% | GrowthRev=+2.8%
EPS next Year (2027-12-31): EPS=23.46 | Chg30d=-0.05% | Revisions=+9% | GrowthEPS=+4.8% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -13% (up=44, down=58)